Operating
D&A
Bristol-Myers Squibb D&A decreased by 39.2% to $594.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 41.3%, from $1.01B to $594.00M. Over 4 years (FY 2021 to FY 2025), D&A shows a downward trend with a -21.7% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
Metric ID:
depreciation_and_amortization_cfHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.71B | $2.73B | $2.58B | $2.58B | $2.58B | $2.59B | $2.52B | $2.43B | $2.43B | $2.44B | $2.46B | $2.53B | $2.60B | $2.59B | $1.88B | $1.01B | $1.01B | $1.01B | $977.00M | $594.00M |
| QoQ Change | — | +0.6% | -5.4% | +0.2% | -0.0% | +0.2% | -2.6% | -3.6% | +0.1% | +0.1% | +1.2% | +2.8% | +2.5% | -0.2% | -27.5% | -46.2% | -0.1% | +0.0% | -3.4% | -39.2% |
| YoY Change | — | — | — | — | -4.8% | -5.1% | -2.2% | -6.0% | -5.8% | -5.9% | -2.3% | +4.2% | +6.7% | +6.4% | -23.7% | -60.0% | -61.1% | -61.0% | -48.0% | -41.3% |
Range$594.00M – $2.73B
CAGR-27.4%
Avg YoY Growth-19.4%
Median YoY Growth-5.9%
Current Streak2 quarters decline
D&A at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's d&a?
- Bristol-Myers Squibb (BMY) reported d&a of $594.00M in Q1 2026.
- How has Bristol-Myers Squibb's d&a changed year-over-year?
- Bristol-Myers Squibb's d&a decreased by 41.3% year-over-year, from $1.01B to $594.00M.
- What is the long-term trend for Bristol-Myers Squibb's d&a?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's d&a has grown at a -21.7% compound annual growth rate (CAGR), from $10.69B to $4.01B.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.